Authors | Number of cases | Age | Histology | Treatment | Follow-up |
---|---|---|---|---|---|
Mornard et al. [24] | 2 | 36–62 | |||
Razeman et al. [25] | 28 | 4: R Mastect 13: WE+LND | 10 recurrences (2 years) | ||
Erdman et al. [26] | 3 | ||||
Khan et al. [27] | 3 | 1: R Mastect 2: M Mastect | 1: Recurrence-free (9 years) 2: Lost from view | ||
Badejo et al. [28] | 2 | 2: R Mastect | 2: Recurrence free (2 and 4 years) | ||
Marino et al. [29] | 2 | 2: WE + RT | 2: Recurrence free (3 years) | ||
Kawahara et al. [30] | 59 | 31–84 | 37 IDC + 3 MC + 1 ApC + 2 Muci C + 1 MC IS | 26: WE+LND 26: R Mastect 2: WE | 5: Nod. Recurrence 54: Recurrence free (1 month to 13 years) |
Haddad et al. [31] | 2 | 1 ILC+ 1 U ADK | 1: neoadj CT+ WE+LND + RT 1: WE+LND + CT + RT + HT | 2 :Recurrence free (1 year) | |
Yanagi et al. [17] | 94 | 26–88 | 52 IDC+ 5MC+ 2ILC+ 5Muci C+ 4 Ap C | 6: neoadj CT + WE + LND or Mastect 84: Surgery (49 WE+ 1 WE+LND+ 3 R Mastect + 18 M Mastect + others) 72: adj treatment (RT +/− CT +/− HT) | 9: Recurrences (3 nodal + 2 local + 2 bone + 1 systemic + 1 peritoneal cavity) |
Our series | 5 | 33–60 | 3 IDC + 1 ILC 1 MC | 1: CT + RT 4: WE+LND + CT + RT +/−HT | 1: Metastasis (2 years) 4: Recurrence free |